A multi-disciplinary symposium highlighting the work of Harvard researchers, faculty, and collaborators on critical questions surrounding the implementation of HIV care and treatment programs globally. Agenda

7:30am-8:00am Continental Breakfast 8:00am-8:15am Welcome – M. Essex (view slides) 8:15am-10:30am Session I: Prevention of Mother-to-Child Transmission (PMTCT) and Antiretroviral (ARV) Therapy Trials & Programs Overview on the Pathophysiology of PMTCT: K. McIntosh (view slides) Botswana: M. Essex (view slides) Tanzania: S. Kapiga (view slides) Thailand: K. McIntosh (view slides) Haiti, Nigeria, Senegal, South Africa, Vietnam: P. Kanki (view slides) Q & A/Discussion 10:30am-10:45am Coffee Break 10:45am-12:30pm Session II: Questions Surrounding PMTCT & Drug Resistance with Emphasis on Drugs Commonly Used in Resource-Scarce Settings Overview on Selection of Drugs for Resource-Scarce Settings: B. Walker (view slides) How Can We Satisfy the Demands for Affordable Testing & Monitoring? S. Graham (view slides) Is There a Role for Nevirapine (NVP) in PMTCT in Developing Countries when NVP or other Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI’s) May be Subsequently Used for Adult ARV Therapy? S. Lockman (view slides) Q & A/Discussion 12:30pm-1:30pm Lunch (provided) 1:30pm-3:00pm Session III: Challenges & Other Considerations What are the Challenges in Scaling-up PMTCT & ARV Programs? R. Marlink (view slides) How should Economic Considerations be Addressed in Designing PMTCT & ARV Programs? K. Freedberg (view slides) What are the Ethical Issues for both ARV Therapy & PMTCT Efforts in the Utilization of ARV Treatment in Developing Countries? D. Wikler (view slides) Q & A/Discussion 3:00pm-3:30pm Final Thoughts/Closing Remarks